Zacks Investment Research | Nov 16, 2017 12:30AM ET
Asia-Pacific, or APAC, is home to more than half of the world's population, so demand for healthcare is also exceptionally high in the region. Furthermore, the need for cutting-edge MedTech products and services is significantly high across the world, with APAC being no exception.
In fact, a research report by McKinsey shows that APAC is expected to outpace the European Union as the world’s second-largest MedTech market pretty soon (after the United States). Almost 1.1 billion people in the region are expected to enter the 50-plus age group by 2025, indicating emerging demand for healthcare needs. Also, APAC accounts for two-thirds of the global disease burden.
Further, a research report by Statista shows that the MedTech market in the Asia-Pacific region is estimated to reach nearly $78 billion in 2018.
Trump’s Focus on Asia
With the above data pointing toward the huge and unmet healthcare needs within the APAC market, investors may find President Trump’s recent 12-day long Asia trip (with stops in Japan, South Korea, China, Vietnam and the Philippines) to be a positive sign.
Furthermore, his recent tweet – “Our great country is respected again in Asia. You will see the fruits of our long but successful trip for many years to come!”–is indicative of a favorable Republican stance on APAC, especially with respect to business and trade.
Here we take a sneak peek at two major postulates of Trump’s recent Asia visit:
Bilateral Trade Agreement
Trump’s promise to augment bilateral trade agreements with Indo-Pacific nations instills our confidence in his APAC policies. However, Trump specifically mentioned that these agreements are bound to follow the "principles of fair and reciprocal trade." He also voiced for “free and open Indo-Pacific trade,” emphasizing on increased focus in the nations of Japan, Australia, and India.
Prospects in China
“Pacific is big enough to accommodate both China and the United States,” said China’s President Xi Jinping during Trump’s visit.
China undoubtedly poses serious competitive threat to the United States, not just in the healthcare space, but also in electronic, semiconductors, retail, and other areas. Jinping’s statements clearly hint at the possibility of the countries coexisting peacefully despite the political tensions. This might also be indicative of strategic mergers between companies in the two nations in order to enhance trade practices.
MedTech Companies Eye APAC
Considering Trump’s growing focus on APAC, the region seems to be poised to yield accretive returns in the long term. In fact, stakeholders in the medical universe have been eyeing the emerging market over the last couple of years. These companies are bullish on the growing medical awareness, economic prosperity, an aging population, increasing wealth, government focus on healthcare infrastructure, and the expansion of medical insurance coverage in the APAC space.
Meanwhile, despite the health-policy debacle in the United States and deteriorating economic conditions in Europe, we can conclude that growth in the emerging markets of China, India, Japan, and others will bolster the global foothold for MedTech companies. Below, we take a look at four leading MedTech players that are tapping into and also gaining from the bountiful opportunities in the APAC market:
Baxter International (NYSE:BAX)
Baxter’s solid presence in Asia, precisely in India, is worth a mention; the company has research hubs in Japan and China. In the just-reported third quarter, Baxter completed the acquisition of India-based Claris Injectables, a global generic injectables pharmaceutical company, for almost $625 million. In December 2016, Baxter had initiated the agreement. Per management, the acquisition will bolster Baxter’s foothold in the generic pharmaceuticals space. In the second quarter of 2017, Baxter signed an agreement with India-based Dorizoe Lifesciences for the expansion of its generic injectables pipeline.
Further, Baxter’s strong presence in peritoneal dialysis, nutrition, IV fluids, and anesthesia gases fortifies its footprint in China.
This Zacks Rank #2 (Buy) stock has had an impressive run on the bourses in the last two years. The stock has returned 70.6%, significantly higher than the broader industry’s gain of 16.2%.
BostonScientific Corporation (NYSE:BSX)
An important part of Boston Scientific’s growth strategy is to continue pursuing development opportunities outside the United States.
In the just-reported third-quarter 2017, business from the emerging markets registered an 18% organic growth rate. It remained above the company’s target of reaching 15% of sales by 2017 (from 8% in 2013). Business in China was also remarkable (up 23% year-over-year). The company is currently looking forward to an improved performance in China, banking on the recent approval of SYNERGY.
Boston Scientific is also optimistic about its core cardiology segment, which is gradually stabilizing with growth in the BRIC nations. The cardiology capacity in China is expected to double by 2017-end. In India, business is projected to grow more than 15% annually.
This Zacks Rank #3 (Hold) stock has yielded a stellar return of 59.3% in the last two years, way ahead of the broader industry’s 16.2% over the same time frame. You can see Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.